Iridex Reports 7 Percent Q2 Revenue Gain

Iridex (NASDAQ:IRIX), a medical device company specializing in laser-based systems for eye disease treatments, reported its second quarter results on August 12, 2025, covering the three months ended June 28. The key news in the release was a return to modest revenue growth while keeping operating expenses lower, which led to a narrower net loss and positive non-GAAP adjusted EBITDA. The company posted GAAP revenue of $13.6 million, compared to $12.6 million in Q2 2024, a 7% increase. Earnings per share (EPS, GAAP) improved to $(0.06), up from $(0.16) in Q2 2024. There were no official analyst estimates to compare against, but the results marked sequential and year-over-year improvement. Overall, declining gross margins remain a concern, yet disciplined expense management and slight growth indicate ongoing efforts to return to profitability.Iridex develops, manufactures, and markets medical laser systems and related devices used to treat glaucoma and retinal diseases. Its portfolio includes advanced proprietary technologies like MicroPulse, which enables precise, tissue-sparing laser treatments favored for their safety and effectiveness. Its business relies on both capital equipment sales and a growing base of recurring revenues from single-use consumable probes and service contracts, which are crucial to stability.Recently, the company has sharpened its focus on cost control, operational discipline, and increasing the adoption of recurring-use consumables such as laser probes. Key success factors include continuous innovation in its proprietary systems, expanding into global growth markets, ensuring high rates of recurring sales from installed equipment, and maintaining compliance with evolving medical regulations. Product differentiation and customer loyalty, especially in a competitive space dominated by larger companies, are also central to its long-term strategy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool